Peptide Synthesis Methods: An Introduction to SPPS
The vast majority of research peptides on the market today are made by solid-phase peptide synthesis, or SPPS. This article walks through the chemistry of how those amino acid chains are actually assembled, purified, and verified.
The SPPS Workflow at a Glance
Before drilling into individual steps, here's the full pipeline a research peptide passes through from sequence design to a finished, characterized lot. Each stage is covered in detail further down.
Sequence design
Confirm the target sequence, decide whether the C-terminus should be an acid or amide, and select the resin and protecting-group strategy accordingly.
Resin loading
Anchor the C-terminal amino acid to the chosen resin, leaving its alpha-amino Fmoc group ready for the first deprotection.
Cycle assembly
Run the deprotection-coupling cycle once per residue, working from C-terminus to N-terminus, with double couplings on difficult positions.
Cleavage and global deprotection
Treat the peptide-resin with a TFA cocktail to release the peptide and remove side-chain protecting groups, then precipitate into cold ether.
Preparative HPLC
Load the crude peptide onto a preparative C18 column and collect fractions corresponding to the target peak. Lyophilize the pooled fractions.
Analytical characterization
Run analytical HPLC for purity, ESI-MS or MALDI-TOF for identity, and (when needed) amino acid analysis to confirm composition.
Lot release and COA generation
If purity, identity, and any optional tests pass spec, the lot is released and the batch-specific Certificate of Analysis is issued for that lot.
Why Solid-Phase, and Why It Won the Nobel
Before 1963, peptides were assembled in solution: each new amino acid was coupled to a growing chain in a flask, the product was isolated, purified, and then carried into the next step. For anything longer than a tripeptide it was painfully slow, the yields collapsed, and side reactions were difficult to control.
R. Bruce Merrifield's insight was simple but transformative — anchor the C-terminus of the peptide to an insoluble polymer bead and run all the chemistry on that bead. Excess reagents and soluble byproducts can be washed away with solvent between every step, while the growing peptide stays bound to the resin. The technique became the dominant method for peptide manufacturing and earned Merrifield the 1984 Nobel Prize in Chemistry.
The Resin: Where the Peptide Lives During Synthesis
Modern SPPS starts with a polystyrene or polyethylene-glycol-based resin functionalized with a linker — a small molecule that anchors the first amino acid and is later cleaved at the end to release the finished peptide. Common choices include Wang resin (yields a free C-terminal carboxylic acid) and Rink amide resin (yields a C-terminal amide). The choice of linker is dictated by what the target peptide's C-terminus needs to look like.
Fmoc Strategy: The Deprotection-Coupling Cycle
The dominant chemistry for research-scale SPPS today is the Fmoc/tBu strategy. Each amino acid building block carries two kinds of protecting groups:
- Fmoc (9-fluorenylmethoxycarbonyl) on the alpha-amino group, removed at the start of every cycle with a mild base — typically 20% piperidine in DMF.
- Acid-labile groups (tBu, Trt, Boc, Pbf, etc.) on reactive side chains such as those of Lys, Arg, Cys, Ser, and Glu, which stay in place until the very end.
One Synthesis Cycle, Repeated Per Residue
- 1
Deprotect
Treat the resin with 20% piperidine in DMF to remove the Fmoc group from the most recently added residue. Wash with DMF.
- 2
Activate and Couple
Pre-activate the next Fmoc-protected amino acid with a coupling reagent (HBTU, HATU, or DIC/Oxyma) and a base such as DIPEA. Apply to the resin so the activated carboxylate forms a new amide bond with the free amine.
- 3
Wash
Flush excess reagents and byproducts off the bead with DMF, then DCM, leaving a clean resin ready for the next cycle.
- 4
Repeat
Return to step 1 for the next residue. A 30-mer peptide therefore involves roughly 30 deprotection-coupling cycles, run sequentially.
A 30-residue peptide therefore involves roughly 30 deprotection-coupling cycles — and several hundred discrete reagent additions, washes, and timed steps. This is why automated peptide synthesizers exist; running this by hand for any length of time introduces variability that shows up later as deletion sequences and other impurities.
Coupling Reagents and What They Do
Forming an amide bond directly between a carboxylic acid and an amine is thermodynamically favorable but kinetically slow. Coupling reagents bridge that gap by activating the carboxylate as a more reactive species — typically an active ester or acyl-uronium — that the incoming amine can attack quickly. The reagent of choice influences both how fast the coupling proceeds and how much epimerization occurs at the alpha-carbon.
HBTU / HATU
Uronium salts
Fast and reliable. HATU is especially effective on sterically hindered residues.
DIC / Oxyma
Carbodiimide + additive
Gained popularity as a safer alternative to HOBt with strong epimerization suppression.
PyBOP
Phosphonium salt
Common choice for cyclization steps and difficult couplings on aggregation-prone sequences.
Difficult Sequences and How They're Tamed
Not all sequences synthesize cleanly. Long stretches of beta-branched residues (Val, Ile, Thr) or aggregation-prone runs can fold the growing peptide chain back on itself, burying the resin-bound amine and slowing or stalling the next coupling. The result is incomplete coupling — a deletion sequence where one residue is missing — which appears later as an impurity peak on HPLC. Standard remedies include double couplings, elevated temperature (microwave-assisted SPPS), use of pseudoproline or Dmb dipeptides to disrupt secondary structure, and switching to a more powerful coupling reagent for the problem residue.
Cleavage and Global Deprotection
Once all residues are in place, the peptide is still tethered to the resin and decorated with side-chain protecting groups. A single cleavage step takes care of both. The standard cocktail is trifluoroacetic acid (TFA) with a small percentage of scavengers such as water, triisopropylsilane, and ethanedithiol. The scavengers trap reactive carbocations released as the protecting groups come off, keeping them from re-attacking sensitive residues like Trp, Met, and Cys. After 1 to 3 hours of cleavage, the resin is filtered off and the peptide is precipitated into cold diethyl ether and pelleted by centrifugation.
Purification and Identity Confirmation
What comes out of cleavage is a mixture: the desired full-length peptide plus deletion sequences, truncated chains, oxidation products, and any side-chain modifications that survived the cocktail. Purification is almost always done by preparative reverse-phase HPLC, typically on a C18 column with a water/acetonitrile gradient buffered with TFA. Fractions are collected, analyzed analytically, pooled, and lyophilized.
The purified material is then characterized by three complementary techniques:
Analytical HPLC
A small portion of the lot is run on an analytical column. Purity is reported as the percent area of the main peak versus all detected impurities — the number that appears on the COA.
Mass Spectrometry
ESI-MS or MALDI-TOF confirms the molecular weight of the main peak matches the theoretical mass of the target sequence within a few daltons. This rules out a same-purity-different-molecule scenario.
Amino Acid Analysis
Hydrolysis-based amino acid analysis or sequencing may be used for higher-stakes lots to verify the actual composition of the chain.
What This Means for the Material in a Research Vial
Understanding the synthesis pipeline makes the numbers on a COA more interpretable. The "98% pure" line is downstream of every choice above: the resin, the protecting-group strategy, the coupling reagent, how aggressively the operator pushed difficult couplings, the cleavage cocktail, and the HPLC method used to purify and analyze the final product. A well-run SPPS lot of a moderate-length peptide — say, 20 to 30 residues — can routinely hit 98%+ purity with mass-spec confirmation. Longer or aggregation-prone sequences are harder, and the difference between a careful lot and a sloppy one shows up clearly on the chromatogram.
For more on how to actually read and verify those documents, see our companion articles on how to read a COA for research peptides and why 98%+ purity matters.
Recombinant and Hybrid Methods (Briefly)
SPPS is not the only way to make a peptide. Larger sequences — typically beyond about 50 residues — start to favor recombinant production in E. coli, yeast, or mammalian cells, where a gene encoding the target is expressed and the peptide is purified from the host. For mid-length sequences, native chemical ligation can stitch two SPPS-made fragments together at a cysteine residue, extending the practical limit of synthetic chemistry. Each route has its own purity profile and its own kinds of contaminating species — host-cell proteins and endotoxins for recombinant material, deletion sequences and side-chain modifications for SPPS — which is why the COA on any lot is specific to the route that produced it.
References
- Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 1963; 85(14): 2149-2154.
- Carpino LA, Han GY. The 9-fluorenylmethoxycarbonyl amino-protecting group. Journal of Organic Chemistry, 1972; 37(22): 3404-3409.
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science, 2016; 22(1): 4-27.
- Albericio F. Developments in peptide and amide synthesis. Current Opinion in Chemical Biology, 2004; 8(3): 211-221.
- Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols, 2007; 2(12): 3247-3256.
- Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers, 2000; 55(3): 227-250.
References are listed for educational purposes only. Citation of any publication, regulatory document, or industry standard does not imply endorsement and should not be interpreted as medical advice or as instructions for human, veterinary, or in-vivo use of any peptide.
Research Use Only
This article is provided for educational purposes for laboratory researchers. The peptides discussed are sold strictly for in-vitro and preclinical research and are not intended for human consumption, veterinary use, food, drug, diagnostic, therapeutic, household, or cosmetic applications.
Lab-Tested Research Peptides
Every Peptide Plus lot ships with a third-party COA that includes the analytical HPLC trace and mass-spec confirmation discussed above.